Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that it will release its third quarter 2025 financial results before markets open on Tuesday, October 28, 2025. The company will host a …
Incyte to Report Third Quarter 2025 Financial Results on October 28 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has granted equity inducement awards to David H. Gardner, its newly appointed Executive Vice President and Chief Strategy Officer, under the company’s 2024 Inducement …
Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer. Gardner will join the company’s Executive Leadership Team, overseeing corporate strategy and …
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate …
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) released new 24-week interim data from its pivotal Phase 3 STOP-HS trials, showing that its oral JAK1 inhibitor povorcitinib (INCB54707) delivered sustained efficacy and …
Incyte Reports Positive 24-Week Data for Povorcitinib in Hidradenitis Suppurativa Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will highlight new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress in Paris, running September 17–20. …
Incyte to Present New Data on Dermatology Portfolio at EADV 2025 Congress Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced the launch of HS TRUTHS, an educational campaign aimed at increasing understanding of hidradenitis suppurativa (HS), a chronic inflammatory skin condition that can …
Incyte Launches HS TRUTHS Campaign to Raise Awareness of Hidradenitis Suppurativa Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has granted equity inducement awards to Soni Basi, the company’s newly appointed Executive Vice President and Chief Human Resources Officer. The awards were issued …
Incyte Grants Equity Awards to New Human Resources Chief Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has appointed Soni Basi as Executive Vice President and Chief Human Resources Officer, effective August 25. She will join the company’s Executive Leadership Team …
Incyte Names Soni Basi as Chief Human Resources Officer Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced plans to participate in several investor conferences throughout September 2025.
Incyte to Present at Multiple Healthcare Investor Conferences in September Read More